Dr Galina Kaseko
Chief Executive Officer 

Dr Kaseko is a co-founder of Anthrocell. A medical doctor with training in immunology and pediatric oncology, she has more than two decades of experience in biomedical research and managing multi-disciplinary biological product development projects in a commercial environment.

Since arriving in Australia, Dr. Kaseko’s career has spanned academia and business. She held research and teaching roles at the University of New South Wales, was involved in the creation of several biotechnology firms, and been an active consultant in both private and public sectors.  Her expertise includes development of human monoclonal antibodies, growth factors and soluble receptors, specific immunity of cancer, auto-immune and infectious diseases, R&D management, compliance policies (including FDA and bio-safety regulations). Intellectual property strategy, and technology valuation. She authored numerous confidential expert reports and served as an expert witness. Dr Kaseko is a co-inventor of Anthrocell’s technology.

A Gold Medal Graduate from the First Moscow State Medical University she was awarded a special fellowship by Russia’s Health Minister to support her Doctoral studies.  She was later personally selected by the President of the Russian Federation for a post-doctoral fellowship in the area of paediatric cancer. In addition to her medical qualifications, Dr. Kaseko holds a Masters degree in Corporate and Intellectual Property Law from The University of New South Wales and is an alumna of Harvard Business School’s General Management Program.

Dr Tohsak Mahaworasilpa
Chief Scientific Officer 

Dr Mahaworasilpa is a co-founder of Anthrocell, and a researcher and inventor in the areas of cell biophysics, immunology and biotechnology. He holds several Australian and international patents, one of which was successfully commercialised as the basis of a biotechnology firm that successfully listed on ASX.

Dr Mahaworasilpa’s research interests include: the dynamics of biological cells in intense electric fields, the electrical properties of cell membranes, the effects of electric fields on the stability and survival of biological cells, the process  of cell membrane breakdown, and cell manipulation, stimulation and modification for the production of biopharmaceutical products.

Dr Mahaworasilpa holds a Bachelor of Science degree from Chulalongkorn University, Bangkok, Thailand, a Master of Science in Medical Physics and a Doctor of Philosophy in Biophysics from the University of New South Wales.

Dr Peter Welburn
Head of Research & Development 

Peter is an experienced and accomplished executive with a track record of successfully driving the clinical performance and commercial outcomes of drug development in Biotech and Pharma organisations in Australia, Europe, and the US.

Over a thirty-five-year career he held senior roles in General Management, Regulatory Affairs, Sales and Marketing, Strategic Planning, and Clinical R&D. From 2001 to 2011 he served as CEO and CSO of Peplin and from 2011 to 2014 was General Manager of Leo Pharma (which acquired Peplin). Earlier in his career he spent 14 years with GlaxoSmithKline in sales, marketing, and product management roles and 7 years with Janssen-Cilag and Ethnor in R&D Management.

Peter holds a BSc (with Honors) from the University of Edinburgh, an MSc in Pharmacology from the University of Sydney and a PhD in Pharmacology from the University of Cardiff. He has an extensive publication record and is a frequent speaker at conferences, international symposia and other high level meetings.

Dr David Chin
Director of Bioprocess Development 

David has worked in biopharmaceuticals for nearly 20 years, with significant experience in recombinant protein expression in both microbial and mammalian cell systems, and monoclonal antibody discovery and engineering.  As an Australian Research Council (ARC) research fellowship recipient he researched various biopharmaceuticals in the fields of oncology and inflammation. With further training in business administration, David has taken up several senior and managing positions.

Prior to joining Anthrocell David was Director of Bio-Production and External Research Collaborations at Biosceptre.  Earlier he was operation manager oat the National Biologics Facility (NBF) at University of Queensland’s Australian Institute for Bioengineering and Nanotechnology, working in the area of recombinant protein production, cell line generation and protein characterisation. In this post David managed over 20 scientific staff controlling a budget of over $A30 million, established over 30 collaborations between the biotech industry and academia and accomplished over 300 commercial and research projects at AIBN.  David was also appointed as Chief Operating Officer at Stem Cell Limited, a commercialisation spin-off from University of Queensland and Monash University.

In addition to his PhD from UNSW and an GradCert in Management from AGSM.

Ms Helen Wray
Project Director, Anthrocell Bioservices 

Helen has worked in senior roles in the commercialisation of therapeutic products for more than 20 years.  With a passion for “start-ups” and taking innovative health technologies to commercial success in local and international markets, Helen has successfully planned and delivered on complex projects across the commercialisation spectrum, including strategy development, licensing, in-house and contract manufacturing, acquisitions, technical and commercial feasibilities, funding, tech transfer, compliance, reimbursement and marketing.

As VP, Operations at Admedus Ltd, Helen led the development and execution of the manufacturing and global logistics strategies for a high risk biological device that ultimately included the acquisition of Verigen Pty Ltd from sanofi Genzyme. As Director of IP and Health Economics at Spirit Pharmaceuticals, Helen managed Spirit’s trade mark portfolio and patent litigation. In addition, she negotiated exclusive licenses for a number of significant generic molecules. As Executive Director of Capra Group, Helen advised universities, early stage private and ASX listed technology companies on matters as diverse as acquisition strategy, technical feasibility, manufacturing and licensing.

Helen received a Bachelor of Science with Honours in Pathology from the University of Western Australia and a Master of Business Administration (Adv) from the same university, where she was Dux of the Innovation and Venture Capital stream. In addition, she completed a Masters in Intellectual Property Law, with a focus on licensing, from the University of Melbourne, is a registered Trade Mark Attorney and Graduate of the Australian Institute of Company Directors.

Mr Sam Burshtein
Director of Corporate Development 

Sam Burshtein has over two decades of experience with technology innovation and new venture strategy that spans executive and academic roles.This includes roles in software development and marketing, strategy and business development consulting (including a period with Boston Consulting Group), and venture capital (with Carmel Ventures).  He was a co-founder and executive of a private university in Israel offering a Masters of Entrepreneurship and Innovation degree (in partnership with Swinburne University), and an advisor to several successful information technology and bio-technology ventures.

As an academic, Mr. Burshtein was as Senior Lecturer in Innovation at Macquarie University (where he led the development of a suite of programs on technology innovation management and research commercialization, and as a Senior Lecturer in Finance at Swinburne University’s Israel program.  He served as Visiting Professor of Technology Management at the University of St Joseph in Macau, and was a Visiting Fellow at Singapore Management University, and was a co-author of  New Venture Creation: A Pacific Rim Perspective, a leading Entrepreneurship text. His research focused on technology based entrepreneurship and commercialisation of innovation.

Mr. Burshtein received a Bachelor of Business (with Distinction and the University Medal) from the University of Technology, Sydney, an MBA in Strategy from the Kellogg Graduate School of Management and a Masters of Applied Science in Bioinformatics from The University of Sydney.


Mr Jeffrey Egan
Communications Manager 

Jeffrey Egan is a senior communications specialist with over 18 years’ experience in stakeholder engagement, government relations, issues management, community consultation and public relations. He has experience in both the public and private sectors across a range of industries including: infrastructure, health and property.Jeff has a comprehensive understanding of government having served as Ministerial Adviser in John Howard’s Liberal/National Government and two terms as a Councillor on Blue Mountains City Council, including a period as Deputy Mayor.

Jeff Egan holds several post graduate qualifications in communications including: a Master’s Degree in Organisational Communication and Graduate Diploma in Communication both from Charles Sturt University, Graduate Certificate of Public Relations from Sydney TAFE , as well as a Bachelor of Education from Australian Catholic University. In addition he also has extensive training in community consultation and stakeholder engagement which includes completing the IAP2 Certificate Course.He is a Member of both the Public Relations Institute of Australia and International Association for Public Participation.